Associations between second-line glucose-lowering combination therapies with metformin and HbA1c , body weight, quality of life, hypoglycaemic events, and glucose-lowering treatment intensification: the DISCOVER study

COMMENTED

Type 2 Diabetes

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme

Diabetes Obes Metab.

Nicolucci A, Charbonnel B, Gomes MB, Khunti K, Kosiborod M, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Razufa J, Fenici P, Hammar N, Surmont F, Tang F, Pocock S

doi: 10.1111/dom.13830.

Diabetes - GeneralType 2 Diabetes

Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study

Diabetologia.

Lu CH, Yang CY, Li CY, Hsieh CY, Ou HT

doi: 10.1007/

Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalisation and mortality records.

Diabetes Obes Metab.

Zghebi SS, Steinke DT, Rutter MK, Emsley RA, Ashcroft DM

doi: 10.1111/dom.12692.

Further Publications

What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated HbA1c (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER study

Diabetes Obes Metab

Bonnet F, Chen H, Cooper A, Gomes MB, Ji L, Leigh P, Gutierrez LR, Shestakova MV, Shimomura I, Siddiqui A, Tang F, Vora J, Watada H, Khunti K

doi: 10.1111/dom.14476

COMMENTED

Type 2 Diabetes

Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes

JAMA Netw Open.

O’Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N, Moran MR, Liss DT, Prospect TA, Ackermann RT

doi: 10.1001/jamanetworkopen.

COMMENTED

Diabetes - GeneralType 2 Diabetes

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study

BMJ

Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S

doi: 10.1136/bmj.k2693.

COMMENTED

Type 2 Diabetes

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

Lancet.

Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S, VERIFY study group.

doi: 10.1016/

Diabetes - GeneralType 2 DiabetesGlycemic Control

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis

JAMA.

Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF

doi: 10.1001/jama.2016.9400.

COMMENTED

Type 2 DiabetesGlycemic Control

Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

doi: 10.2337/dc19-1769.

Diabetes + Endocrinology

Associations between second-line glucose-lowering combination therapies with metformin and HbA_1c , body weight, quality of life, hypoglycaemic events, and glucose-lowering treatment intensification: the DISCOVER study

Related content

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme

Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study

Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalisation and mortality records.

What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated HbA1c (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER study

Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes

Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis

Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight